HEPHAISTOS is a Franco-Belgian company specializing in immunotherapy, dedicated to designing and developing “Immune Sensor Modulators” (ISM) to address a major challenge in oncology: transforming “cold” tumors resistant to immunotherapy into “hot” targets for the immune system.
Award-winning and grant-funded multiple times, HEPHAISTOS was co-founded by Martine CAROFF, an emeritus director at CNRS, European Woman Innovator 2019, and a pioneer in the biochemistry of bacterial TLR4 agonists. In 2024, the company secured €10.3 million in seed funding, notably with ELAIA and XISTA, as well as non-dilutive funding from the EIC Accelerator and France 2030.
- Control of Chemical Manufacturing (CMC) and GMP Transfer:
Dr. Martine CAROFF, Dr. Alexey NOKIKOV, Dr. Christophe ANSIAUX - Pre-clinical development:
Dr. Jérôme KERZERHO, Dr. Capucine PHELIP, Dr. Anaïs DEBESSET - Strategic, administrative and financial management:
Frédéric CAROFF, Simon PICO, Christel LONNEUX
HEPHAISTOS teams involved in SyStInn RHU project
HEPHAISTOS Scientific and Technical Manager
Frédéric CAROFF,
CEO
